In the summer of 2009, as CEO of the trade group BayBio, I invited a former biotech CEO and member of the National Academy of Sciences to meet over the topic of succession planning. I invited this friend to consider becoming the next CEO of BayBio, as the industry needed a leader capable of delivering BayBio to new heights. My friend said no.
“There are too many biotech organizations in California,” was the reply. I heartily agreed. In fact, since 2005 I had been expounding the virtue of a single voice.